Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor
(EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non …

The development of EGFR kinase inhibitors to treat non-small cell lung cancers is an
important medical necessity due to persistent development of resistance by the mutations. In …

Background Anlotinib showed significant survival benefits in advanced non‐small cell lung
cancer (NSCLC) patients as a third‐or further‐line treatment in the ALTER0303 trial. We …

Current clinical trials of combined EGFR-tyrosine kinase inhibitors (TKI) and immune
checkpoint blockade (ICB) therapies show no additional effect. This raises questions …

Introduction Squamous-cell carcinoma (SCC) of the lung represents around 20% of non-
small cell lung cancers. Although activating mutations of EGFR are rare in this subtype, its …

To investigate the exposure–safety relationships of afatinib in Japanese population, we
performed population pharmacokinetics (PK) analysis of afatinib in Japanese advanced non …

Introduction The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas
(LUADs) has been well established; however, the benefit for EGFR-mutant or ALK …

Despite advances in molecular characterization and lung cancer treatment in recent years,
treatment options for patients diagnosed with squamous cell carcinoma of the lung (SCC) …

Afatinib is a pan‐HER inhibitor approved for specific types of lung cancer. We explored
antitumor activity, predictive biomarkers and the potential mechanisms underlying antitumor …

Abstract Afatinib (Giotrif®, Gilotrif®) is an orally administered, irreversible inhibitor of the
ErbB family of tyrosine kinases. In the first-line treatment of patients with advanced lung …